CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Dexmedetomidine Hydrochloride +1 moredrug
Likely dose
Dexmedetomidine Hydrochloride 20 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04968392
NCT04968392Phase 3Completed

Analgesic Efficacy of Single-shot Adductor Canal Block With Levobupivacaine and Dexmedetomidine in Total Knee Arthroplasty: a Randomized Clinical Trial

Assiut University·interventional·Posted Jul 20, 2021·Updated Jul 20, 2021

In Brief

A Phase 3 clinical trial evaluating Dexmedetomidine Hydrochloride and Levobupivacaine for Adductor Canal Block and 2 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Total knee arthroplasty surgery is associated with severe postoperative pain and adequate pain management is necessary for early postoperative mobilization and rehabilitation. Although good postoperative pain control may be achieved by continuous epidural anesthesia or femoral nerve block, both methods have adverse effects such as muscle weakness, which may delay postoperative mobilization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 20, 2021
Enrollment StartMar 1, 2019
Primary CompletionFeb 1, 2020
Study CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.0 years ago

Interventions

Dexmedetomidine Hydrochloridedrug

20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine

Levobupivacainedrug

20 mL of 0.25% levobupivacaine plus 1 mL normal saline